ANI Pharmaceuticals (ANIP)

[Easka]

Revenue forecasting on generic and branded drugs has certainly been the issue over the last 3 qtrs. Art at least gave more of an explanation on what has been happening. One quote from him "two new competitors come in and the price drops in half overnight." Then they have to match, (if possible) to keep their market share. If not they will exit that drug, as they did with Methy ER. Also per Art, "a lot of desperation with some of the competitors, there needs to be more industry consolidation." Sounds like more opportunity for M/A coming with "cash strapped" competitors. Not sure they have current product forecasting figured out yet. Corti still on track, Still by far the biggest plus.